PROPANC BIOPHARMA, INC.

PPCB ·Healthcare, Drug Manufacturers - General, Australia
Financial Statements Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2017 FY2016 FY2015 FY2014 FY2013 FY2012 FY2011 FY2010
Operating Activities
Net Income $-7.9M $-9.4M $-3.4M $-829.6K $-1.4M $-11.4M $-2.2M $-842.5K
Depreciation & Amortization $4.1K $1.8K $1.9K
Depreciation $2.2K $877 $81 $538 $4.1K $1.8K $1.9K
Amortization
Stock-Based Compensation $1.7M $1.7M
Net Cash from Operating Activities $-2.1M $-4.5M $-1.4M $226.4K $-128.6K $-170.3K $-1.4M
Investing Activities
Capital Expenditures $9.9K $3.9K $0 $3.5K
Business Acquisitions
Net Cash from Investing Activities $-5.6K $0 $-29.2K
Financing Activities
Dividends Paid
Stock Repurchases
Net Cash from Financing Activities $2.1M $128.5K $170.3K $1.4M
Net Change in Cash
Free Cash Flow $-4.5M $-1.4M $226.4K $-1.4M
← Newer Page 2 of 3 Older →